Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at ...

A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...

EMA grants orphan designation to Sanofi’s rilzabrutinib, a reversible covalent BTK inhibitor, for IgG4-related disease: Paris Saturday, August 16, 2025, 09:00 Hrs [IST] Sanofi a ...

Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI ...

Rilzabrutinib is an investigational, oral, reversible Bruton tyrosine kinase (BTK) inhibitor. Preclinical findings show the drug reduces vaso-occlusion, markers of inflammation, and adhesion in ...

SAN DIEGO — Rilzabrutinib treatment led to rapid, stable and durable platelet responses among patients with relapsed immune thrombocytopenia, according to data presented at ASH Annual Meeting ...

Sanofi has announced positive results for rilzabrutinib in a phase 3 study that achieved its primary endpoint of durable platelet response in adult patients with persistent or chronic immune ...

Rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of immune thrombocytopenia (ITP).

Paris: Sanofi has announced that the European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible ...

Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing ...